Cargando…

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

BACKGROUND: The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD). METHODS: The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-...

Descripción completa

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217655/ https://www.ncbi.nlm.nih.gov/pubmed/35238940 http://dx.doi.org/10.1093/ndt/gfac040

Ejemplares similares

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
por: Zinman, Bernard, et al.
Publicado: (2014)

Empa's New Clothes: The Untold Story of the Empa-Reg Outcome Trial
por: Alzaid, Aus
Publicado: (2017)

Bladder cancer in the EMPA-REG OUTCOME trial
por: Kohler, Sven, et al.
Publicado: (2017)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
por: Hundertmark, Moritz J., et al.
Publicado: (2021)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
por: Fitchett, David, et al.
Publicado: (2021)

NIMS and Empa announce STAM collaboration
por: Yoshida, Toyonobu, et al.
Publicado: (2014)

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design
por: Fujiki, Shinya, et al.
Publicado: (2020)

Optimal design of cluster randomised trials with continuous recruitment and prospective baseline period
por: Hooper, Richard, et al.
Publicado: (2021)

EMPAS: Electron Microscopy Screening for Endogenous Protein Architectures
por: Kim, Gijeong, et al.
Publicado: (2020)

Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria
por: Verma, Subodh, et al.
Publicado: (2023)

Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Emergency Medicine Physician Assistant (EMPA) Postgraduate Training Programs: Program Characteristics and Training Curricula
por: Kraus, Chadd K., et al.
Publicado: (2018)

Emergency Medicine Physician Assistant (EMPA) Postgraduate Training Programs: Program Characteristics and Training Curricula
por: Wu, Fred
Publicado: (2019)

Design and baseline characteristics of the LANDMARK study
por: Ogata, Hiroaki, et al.
Publicado: (2016)

Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial
por: Singh, Ajay K, et al.
Publicado: (2021)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial
por: Kadowaki, Takashi, et al.
Publicado: (2019)

SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review
por: Rastogi, Ashu, et al.
Publicado: (2017)

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2020)

Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B
por: Shan, Shan, et al.
Publicado: (2019)

Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME(®)
por: Langslet, Gisle, et al.
Publicado: (2020)

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
por: Fitchett, David, et al.
Publicado: (2019)

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
por: Ampudia-Blasco, Francisco Javier, et al.
Publicado: (2017)

Gel shift analysis of the empA promoter region in Vibrio anguillarum
por: Denkin, Steven M, et al.
Publicado: (2004)

The LIFE Cognition Study: design and baseline characteristics
por: Sink, Kaycee M, et al.
Publicado: (2014)

Implementation, recruitment and baseline characteristics: A randomized trial of combined treatments for smoking cessation and weight control
por: Bush, Terry, et al.
Publicado: (2017)

Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
por: Inzucchi, Silvio E, et al.
Publicado: (2020)

Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME
por: Verma, Subodh, et al.
Publicado: (2021)

Codeveloping an effective EMPA to maturity in an acute NHS Trust: an implementer report
por: Silva, Geeth, et al.
Publicado: (2022)

The EMPA-REG outcome study: critical appraisal and potential clinical implications
por: Perseghin, Gianluca, et al.
Publicado: (2016)

The Korean Hypertension Cohort study: design and baseline characteristics
por: Lee, Hae-Young, et al.
Publicado: (2021)

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
por: Wheeler, David C, et al.
Publicado: (2020)

Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial
por: Schernthaner, G., et al.
Publicado: (2016)

Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond
por: Oral, Elif A
Publicado: (2016)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)

Design, Recruitment, and Baseline Characteristics of a Virtual 1-Year Mental Health Study on Behavioral Data and Health Outcomes: Observational Study
por: Kumar, Shefali, et al.
Publicado: (2020)

FIB-FESEM and EMPA results on Antoninianus silver coins for manufacturing and corrosion processes
por: Doménech-Carbó, María Teresa, et al.
Publicado: (2018)

The Indian Chronic Kidney Disease (ICKD) study: baseline characteristics
por: Kumar, Vivek, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1lqa0qsiglal4solkt2o3rs2b9